Low-dose GOS prebiotic trial in healthy Dutch women
258 fecal metagenome samples from 88 healthy women (42-70y) in the Netherlands, in a randomized, parallel, double-blind trial testing low-dose (1.3g or 2.0g) GOS supplementation on Bifidobacterium abundance. machine-written summary
258 samples · 258 runs · NL · Adult · 2024 · 2.07 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 1,032 sample values (collection date, country, subject id, timepoint) |
| ✓ Abstract / description | 516 sample values (health condition, health condition detail) |
| ✓ Full text | 1,032 sample values (antibiotic exposure, location locality, location site, sex) · PMC11366710 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Prebiotic / dietary fibre supplement design randomized_controlled_trial · population healthy_control · Low-dose GOS (1.3 or 2.0g/day) for 3 weeks vs control period
“randomized to consume either 1.3 or 2.0g of GOS per day” — bioproject.description (study level; per-sample arms are in the intervention column below)
longitudinal — not resolved
86 of 86 people sampled more than once (258 samples; median 3, up to 3 per person). Schedule stated by the source: “Fecal samples at start of control (t=-3wk), end of control (t=0), end of 3-week intervention (t=3wk); 3 repeated measures per subject.”; stated follow-up 42 d.
Genera, mean relative abundance over 235 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 258 | 100% | ||||
| country | 258 | 100% | 258 | |||
| health_condition | 258 | 100% | 258 | |||
| subject_id | 258 | 100% | 258 | |||
| antibiotic_exposure | 258 | 100% | 258 | |||
| collection_date | 258 | 100% | 258 | |||
| detailed_location | 258 | 100% | ||||
| health_condition_detail | 258 | 100% | 258 | |||
| location_locality | 258 | 100% | 258 | |||
| location_site | 258 | 100% | 258 | |||
| sex | 258 | 100% | 258 | |||
| timepoint_label | 258 | 100% | 258 |
- A double-blind intervention trial in healthy women demonstrates the beneficial impact on <i>Bifidobacterium</i> with low dosages of prebiotic galacto-oligosaccharides. 2024 PMID 39224188 PMC11366710 own_data
Archive description
Galacto-oligosaccharides (GOS) are well-substantiated prebiotic substrates. Multiple studies have demonstrated a positive impact of GOS on gut microbiota composition and activity, sofar mainly related to Bifidobacterium. However, data on the beneficial impact at lower dosages in a healthy female population are limited. The primary aim of the current study was to reveal the effect of low dosages (1.3 and 2.0g) of GOS on fecal Bifidobacterium abundance in healthy women. Other outcomes included the effect of low dosage of GOS on overall fecal microbiota composition and on self-perceived GI comfort, sleep quality and mental wellbeing.Method: Eighty-eight healthy women (42-70 y, BMI 18.7-30 kg/m 2 ) were included in this randomized, parallel, double-blind study of 6 weeks. The participants were stratified for fiber intake, BMI and age and randomized to consume either 1.3 or 2.0g of GOS per day for 3 weeks after a control period of 3 weeks without any intervention. Fecal samples were collected for shotgun metagenomics sequencing at the start (t=-3) and end (t=0) of the control period and at the end of the intervention period (t=3). Self-perceived gut comfort, sleep quality, and mental wellbeing were assessed weekly. Hierarchical clustering of principal components was applied to data collected from study participants.The relative abundance of Bifidobacterium in feces increased significantly after 3 weeks of daily consumption of both 1.3g (p<0.01) and 2.0g GOS (p<0.01). This was accompanied by a significant shift in the overall microbiota composition for the dosage of 2.0g GOS (p<0.01). Participants that showed a larger increase in Bifidobacterium in the intervention period compared to the change in Bifidobacterium in the control period, defined as responders, showed a significant overall difference in initial fecal microbiota composition as compared to non-responders (p=0.04) and a trend towards lower baseline levels of Bifidobacterium in responders (p=0.10).Daily consumption of a low dose of GOS can lead to an increase in the relative abundance of Bifidobacterium in feces of healthy women. Additionally, with 2.0g GOS, the enrichment of Bifidobacterium is accompanied with a shift in the overall microbiota composition.The study was registered at clinicaltrials.gov, identifier NCT05762965.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of adult by sonnet_x2 with confidence 0.75. Assay shotgun_dna.
- host study.title · “healthy women”
- body site study.description · “fecal Bifidobacterium abundance in healthy women”
- life stage study.description · “Eighty-eight healthy women (42-70 y”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMEA115905584 | antibiotic_exposure | no | R3 | 0.70 | paper.fulltext.methods | using antibiotics less than 3 months before the start |
| SAMEA115905584 | collection_date | 2023-01-01 | R1 | 0.90 | biosample.attribute:collection_date | 2023-01-01 |
| SAMEA115905584 | country | NL | R1 | 0.90 | sample.attr.geographic_location_country_and_or_sea | Netherlands |
| SAMEA115905584 | health_condition | healthy_control | R4 | 0.50 | study.description | Eighty-eight healthy women (42-70 y, BMI 18.7-30 kg/m 2 ) |
| SAMEA115905584 | health_condition_detail | Healthy women | R4 | 0.50 | study.description | Eighty-eight healthy women (42-70 y, BMI 18.7-30 kg/m 2 ) |
| SAMEA115905584 | location_locality | Wageningen | R3 | 0.70 | paper.fulltext.methods | Participants were recruited in the area of Wageningen |
| SAMEA115905584 | location_site | Wageningen Food and Biobased Research (WFBR) | R3 | 0.70 | paper.fulltext.methods | trial was conducted at Wageningen Food and Biobased Research |
| SAMEA115905584 | sex | female | R3 | 0.70 | paper.fulltext.abstract | Eighty-eight healthy women |
| SAMEA115905584 | subject_id | 1 | R1 | 0.70 | sample.name_rule:title | Sample_1_T1 |
| SAMEA115905584 | timepoint_label | 1 | R1 | 0.70 | sample.name_rule:title | Sample_1_T1 |
Sequencing
258 runs over 258 samples · mean 2.09 Gbp per run (median 2.07 Gbp, total 540.19 Gbp; 258 runs with a base count) · layout PAIRED 258 · platform ILLUMINA 258 · models Illumina NovaSeq 6000 (258) · 91% of runs with a Sandpiper profile · first public 2024-08-07
Authors (7)
Looijesteijn E first · Schoemaker MH · van den Belt M · Hester ER · Kortman GAM · Viskaal-van Dongen M · Nauta A last
Downloads
PRJEB78698.csv.gz (7.4 KB) · parquet (79.5 KB) — all 258 samples, every field with route and confidence · PRJEB78698_determinations.csv.gz (16.0 KB) — 2,580 evidence rows